|Delayed - 01/25 11:35:24 am|
IXICO : to Present at Innovation Forum
|02/10/2020 | 04:18am|
|RNS Reach Story|
|Go to market news section|
10 February 2020
('IXICO' or the 'Company')
IXICO to Present at the Annual Shares Magazine/Cenkos Growth and Innovation Forum
on 11th February 2020IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that the Company will be attending and presenting at the Shares Magazine/Cenkos Growth and Innovation Forum on Tuesday, 11 February 2020 at the London Business Design Centre.
Giulio Cerroni, IXICO's Chief Executive Officer, will be attending the event and presenting at 12:15pm GMT in the Flowers Room.
Presentation: 12:15 PM GMT, 11 February 2020, Flowers Room
Exhibition: 09:00 AM - 5:00 PM GMT, 11 February 2020, Booth 25
London - Business Design Centre, London N1 52 Upper Street, Islington
The Shares Magazine/Cenkos Growth and Innovation Forum is one of the UK's major growth and technology focussed investment shows connecting investment experts, fund managers, company executives from fast-growing and technology-led London-listed companies.
For further information please contact:
+44 (0) 20 3763 7498
Alison Howie, Chief Product Officer
Optimum Strategic Communications
+44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manel Mateus
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of Artificial Intelligence (AI) in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
|London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.|
|©2014London Stock Exchange plc. All rights reserved|
IXICO to Present at Innovation Forum - RNS
IXICO plc published this content on 10 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 February 2020 09:17:03 UTC